Kornimate/medical-research-clean huggingface dataset:
incidence of chronic pain after thoracic surgery

Conditions: Postoperative Pain; Postoperative Pain, Acute; Postoperative Pain, Chronic; Video-Assisted Thoracoscopic Surgery; Thoracotomy

Summary: thoracotomy and video-assisted thoracic surgery procedures are frequently performed in thoracic surgery. it is widely accepted that thoracotomy causes severe acute pain. this prolongs the discharge time of the patients, and increases the frequency of postoperative pulmonary complications and postoperative morbidity. postoperative acute pain may cause chronic thoracotomy pain in the later period, and may adversely affect the quality of life of the patients. video-assisted thoracic surgery (vats) has become the standard procedure in minor and major lung surgeries. postoperative pain is seen in patients undergoing vats, although it is not as severe as after thoracotomy. as in thoracotomy, this affects the postoperative pulmonary complications and the discharge time of the patients. likewise, this pain can cause chronic pain. in this study, it was aimed to analyze the symptoms of chronic pain in the 3rd and 6th months postoperatively in patients who had undergone thoracic surgery.


Eligibility criteria:
inclusion criteria: * age between 18 and 65 years * american society of anesthesiologists physical status i-ii-iii * body mass index between 18-35 kg/m2 * patients undergoing elective thoracic surgery exclusion criteria: * advanced cancer * history of chronic analgesic therapy * patients with previous thoracic surgery * patients who were operated under emergency conditions

Keywords: postoperative pain postoperative pain, acute postoperative pain, chronic video-assisted thoracoscopic surgery thoracotomy
to evaluate safety and effectiveness of transcatheter aortic valve system in patients with severe aortic insufficiency

Conditions: Aortic Insufficiency

Summary: to evaluate the safety and effectiveness of transcatheter aortic valve system ( chengdu silara medtech inc. ,chengdu, china)in patients with severe symptomatic aortic insufficiency

transcatheter aortic valve system (chengdu silara medtech inc. ,chengdu, china) will be used for this study. to evaluate the feasibility , safety and effectiveness of transcatheter aortic valve system.

Eligibility criteria:
inclusion criteria: 1. age ≥ 60 years old; 2. subjects with symptomatic severe aortic valve regurgitation. 3. nyha functional class ≥ii. 4. life expectancy after aortic valve implantation thought to be \>1 year， 5. native valvular or peripheral vascular anatomy is appropriate for tavr. 6. patient is assessed by at least two cardiothoracic surgeons and recorded as not suitable for surgery (defined as a risk of operative mortality after 30 days\>50%，or severe irreversible comorbidities or other factors affecting surgery (e.g., porcelain aorta, frailty, chest malformation, severe liver disease, severe lung disease, etc.)), or patients at high risk of surgery（euroscore≥20%, or sts≥8）,or patient not agree open surgery. 7. patient can understand the purpose of the study, voluntarily participates and signs the informed consent form and is willing to accept the relevant examination and clinical follow-up visits. exclusion criteria: 1. anatomy is not appropriate for percutaneous valve implantation. native valve annulus diameter is not in the scope of application(native tav diameter ≤20mm,or ≥28mm 2. evidence of an acute myocardial infarction within 30 days prior to the study procedure, defined as: q-wave myocardial infarction, or non-q-wave myocardial infarction, with ck-mb≥ 2x normal and/or elevated tn (who definition). 3. any treatment for traumatic cardiac surgery within 30 day prior to the study procedure(except coronary revascularization). 4. hematological abnormality, defined as: leukopenia (wbc \<3×109/l), acute anemia (hb \<90g/l), or thrombocytopenia (platelet count\<50×109/l), history of bleeding diathesis or coagulopathy. 5. severe ventricular insufficiency. left ventricular ejection fraction (lvef) \<20%. 6. echocardiographic evidence of intra-cardiac thrombus or vegetation etc. 7. active pepticulcer or upper gi bleeding within 3 months prior to the study procedure. 8. cerebral vascular accident (cva) within 3 months prior to the study procedure,including tia. 9. a known hypersensitivity or contraindication to aspirin, heparin, ticlopidine , clopidogrel and high polymer material, or sensitivity to contrast media, which cannot be adequately pre-medicated. 10. patients with infective endocarditis or other active stage of infection. currently participating in an investigational drug or another device trial.
pharmacological and behavioral treatment of insomnia

Conditions: Lung Diseases; Sleep; Sleep Initiation and Maintenance Disorders

Summary: to develop the maximally effective treatment strategy for chronic sleep-onset insomnia and to reduce its impact on psychological functioning, health, and economic sequelae.

design narrative: the study examined the relative efficacy of a pharmacologic, cognitive behavioral, and conjoint pharmacological/behavioral intervention for chronic sleep-onset insomnia. sixty-three medication-free, chronic sleep-onset insomniacs completed evaluations, baseline sleep diaries, daytime functioning and mood inventories and home-based objective sleep assessments (osa). subjects were then randomized to one of four interventions: 1) six week zolpidem intervention (d for drug); 2) six week multifactor behavioral intervention (b for behavioral); 3) six week conjoint zolpidem and multifactor behavioral intervention (db); and 4) placebo medication intervention (p for placebo). the main outcome measures were sleep-onset latency as measured by sleep diaries; secondary measures included sleep diary measures of sleep efficiency and total sleep time, objective measures of sleep variables (nightcap sleep monitor recorder), and measures of daytime functioning. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
a randomized, controlled trial of inspiratory muscle training (imt)in the icu and ccu

Conditions: Critically Ill; Respiratory Failure

Summary: inspiratory muscle training (imt) is an intervention used with success in the outpatient setting within the copd population. use of imt is also theoretically possible during mechanical ventilation. this study will will assess the feasibility and safety of the study of imt in the patient population.


Eligibility criteria:
inclusion criteria: * mechanically ventilated patients. * must have passed spontaneuos brething trial screening but failed the trial itself. * potential subject must be able to perform atleast 5 minutes of spontaneous breathing trial. exclusion criteria: * known neuromuscular disease * unstable cardiac ischemia * tracheostomized patients

Keywords: critically ill intubated safety feasibility inspiratory muscle training
prophylaxis with single versus five dose of antibiotic therapy as treatment of patients with gangrenous acute appendicitis

Conditions: Gangrenous Appendicitis

Summary: a prospective, randomized controlled clinical trial was conducted at the hospital universitario de santander to test the effectiveness of providing a single 1-dose therapy of antibiotic prophylaxis versus a 5-day antibiotic therapy in patients with acute gangrenous appendicitis.

introduction: for patients with acute gangrenous appendicitis, it is common to provide antibiotics during 5-7 days in order to reduce the incidence of infection of the surgical wound; however the benefit of such treatment has not been tested. a prospective, randomized controlled clinical trial was conducted at the hospital universitario de santander to test the effectiveness of providing a single 1-dose therapy of antibiotic prophylaxis versus a 5-day antibiotic therapy in patients with acute gangrenous appendicitis. materials and methods: from december 2007 to november 2009, 799 patients went through surgery after being diagnosed with acute appendicitis. out of this set, 150 patients diagnosed with acute gangrenous appendicitis, were randomly assigned to one of two groups: control group (group a: 72 patients received a 5-day antibiotic therapy), and treatment group (group b: 78 patients received a single 1-dose of antibiotic prophylaxis). the experimental outcomes included: the incidence of infection of the surgical wound, the length of the hospital stay, and the adverse effects derived from a prolonged use of antibiotics.

Eligibility criteria:
inclusion criteria: * patients with diagnosis of acute appendicitis with intraoperative finding of a gangrenous appendix who accepted to enter the study exclusion criteria: * patients under 12 or older 65 years old * patients with possible immunosuppression such as diabetes, cancer, kidney failure, liver failure * pregnancy * patients who have received antibiotic treatment within seven days before surgery * patients difficult to monitor or follow up

Keywords: acute appendicitis antibiotic prophylaxis wound infection nosocomial infection
metabolic risk factors and myocardial oxygenation reserve

Conditions: Metabolic Syndrome

Summary: the purpose of this study is to use mri images using the os-cmr technique to view the differences in the hearts of healthy volunteers and participants with a condition called metabolic syndrome. the objectives of this project are to compare these two groups and to view how health risks, blood test results, and the time since a metabolic diagnosis can affect heart health.

myocardial oxygenation changes during vasoactive breathing maneuvers, observed with oxygenation-sensitive cardiac mri, will be identified and compared between individuals considered healthy and those fitting the criteria of the metabolic syndrome.

Eligibility criteria:
inclusion criteria: patient participants: * age 18-80 * informed consent * diagnosis of mets (through at least 3 mets characteristics (abdominal obesity, high triglyceride level, low hdl cholesterol, high systolic blood pressure, and high fasting glucose levels) healthy volunteers: * age 18-80 * no known current or pre-existing significant medical problems that would affect the cardiovascular or respiratory system * no smoking exclusion criteria: * general mri contraindications\* * pacemakers, defibrillating wires, implanted defibrillators, intracranial aneurysm clips, metallic foreign bodies in the eyes, knowledge or suspicion of pregnancy. * consumption of caffeine (coffee, tea, cocoa, chocolate, "energy drink") during the 12 hours prior to the exam

Keywords: myocardial oxygenation
exercise and nutrition interventions during chemotherapy k07

Conditions: Neuropathy;Peripheral

Summary: chemotherapy-induced peripheral neuropathy (cipn) is a highly prevalent and severe side-effect of taxane chemotherapy, often used to treat breast cancer. unfortunately there are very limited treatments for cipn. this is a phase ii randomized controlled trial to test the preliminary efficacy of exercise vs. nutrition education on cipn, to systematically investigate the potential roles of inflammation and interoception, and to obtain data with a more accurate effect size to inform a future study.


Eligibility criteria:
inclusion criteria (subjects must...) 1. be female 2. have breast cancer 3. be scheduled to receive taxane chemotherapy without other neurotoxic chemotherapy (platinums, vinca alkaloids, bortezomib, thalidomide) 4. have at least six months life expectancy according to the patient's oncologist or designee 5. be able to read english 6. be at least 18 years old (no upper limit on age) 7. provide written informed consent exclusion criteria (subjects must not...) 1. be in the active or maintenance stage of exercise behavior (i.e., subjects must be sedentary) 2. have physical limitations (e.g., cardiorespiratory, orthopedic, central nervous system) that contraindicate participation in maximal physiological fitness testing and a low/moderate intensity home-based walking and progressive resistance exercise program. additional exclusion criteria only for patients performing the mri scanning (40 of 80 enrolled subjects) 1. subjects must not have contraindications for mri scanning (pacemaker, metal implants, pregnancy, chest expander from breast reconstruction, etc.-note that most port-a-caths are safe for mri scanning)

Keywords: chemotherapy
a study of the safety and effectiveness of apixaban in preventing blood clots in children with leukemia who have a central venous catheter and are treated with asparaginase

Conditions: Lymphoma; Acute Lymphoblastic Leukemia

Summary: the purpose of this study is to compare the effect of a blood thinning drug called apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma. patients must be receiving chemotherapy, including asparaginase, and have a central line (a catheter inserted for administration of medications and blood sampling)


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * new diagnosis of de novo all, lymphomas (t or b cell), or mixed-phenotype acute leukemia * planned 3-4 drug systemic induction chemotherapy with a corticosteroid, vincristine and a single dose or multiple doses of asparaginase, with or without daunorubicin * functioning central venous access device * must be able to tolerate oral medication or have it administered via an nasogastric tube (ngt) or gt tube * males and females,age 1 year(365 days) to \< 18 (17 years and 364 days) years. exclusion criteria: * subjects scheduled to have \> 3 lumbar punctures over the course of the study treatment period * prior history of documented dvt or pe in the past 3 months * known inherited bleeding disorder or coagulopathy * major surgery \[excluding central venous access device (cvad) replacement and bone marrow aspiration and non-open biopsy\] within the last 7 days prior to enrollment that may be associated with a risk of bleeding. open biopsy is considered a major surgery. * uncontrolled severe hypertension at enrollment. severe hypertension is defined as a systolic or diastolic blood pressure (bp) \> 5 mm hg above the 95th percentile as defined by the national high blood pressure education program working group (nhbpep) established guidelines for the definition of normal and elevated blood pressure in children * extreme hyperleukocytosis, white blood cell (wbc) counts over 200 x 109/l (200,000/microl) at the time of enrollment * liver dysfunction manifested by sgtp (alt) \> 5x upper limit of normal (uln) and/or aspartate aminotransferase (ast) \>5 x uln and/or direct (conjugated) bilirubin \> 2x uln * renal function \< 30% of normal for age and size as determined by the schwartz formula * international normalized ratio (inr) \> 1.4 and activated partial thromboplastin time (aptt) \> 3 seconds above the upper limit of normal for age, within 1 week prior to enrollment. * history of allergy to apixaban or factor xa inhibitors * history of significant adverse reaction or major bleeding related adverse reaction to other anticoagulant or antiplatelet agents * history of any significant drug allergy (such as anaphylaxis or hepatotoxicity * any investigational drug being administered during the study other protocol inclusion/exclusion criteria may apply

Keywords: anticoagulation
evaluation of sores treatment by oxygenotherapy

Conditions: Ulcer Venous

Summary: patient with chronic wounds are selected to receive natrox system ; it's a continous diffusion of oxygen therapy delivery system. this one is put on the wound during a consultation at the hospital and will be followed in home medical care. every 2 days a nurse renew the application at home and patient recharge the system with oxygen every day. the complete treatment is prescribe for 4 weeks and at the end patient comes to hospital to have a consultation with the doctor.


Eligibility criteria:
inclusion criteria: * age \> 18 years * accepted to participate * patients followed in vascular medicine and entrusted to the home medical care for the bandages of chronic wounds with apathetic ulcers, not presenting of granulation tissue on their surface exclusion criteria: * infected ulcers * necrosed ulcers * arterial ulcers requiring a revascularisation. * ulcers whose surface is superior in 10x10 cm.
sunitinib as maintenance therapy in treating patients with stage iii or stage iv non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: rationale: sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. it is not yet known whether sunitinib is effective in treating non-small cell lung cancer. purpose: this phase ii trial is studying sunitinib to see how well it works when given as maintenance therapy in treating patients with stage iii or stage iv non-small cell lung cancer which is previously treated with combination chemotherapy.

objectives: primary * to investigate the effect of sunitinib malate on the progression-free survival of patients with stage iiib or iv non-small cell lung cancer secondary * to evaluate the toxicity of sunitinib when administered in the maintenance setting. * to evaluate the additional response rate to sunitinib malate when administered in the maintenance setting. * to evaluate the overall survival of patients treated with sunitinib. after completion of study treatment, patients are followed every 2 months for 1 year, every 6 months for 1 year, and periodically for 3 years.

Eligibility criteria:
inclusion criteria: * no evidence of symptomatic or untreated brain metastases, spinal cord compression, or carcinomatous meningitis * histologically or cytologically confirmed primary non-small cell lung cancer who have stable or responding disease after prior treatment with 3-6 courses of platinum -based therapy * not a candidate for combined modality therapy * no cavitary lesions exclusion criteria: * evidence of symptomatic or untreated brain metastases, spinal cord compression, or carcinomatous meningitis

Keywords: non-small cell lung cancer
impact of sodium-glucose cotransporter 2 inhibitors on post-operative atrial fibrillation in cardiothoracic surgery

Conditions: Atrial Fibrillation

Summary: sglt2 inhibitors are oral anti-diabetic medications that were found to improve cardiorenal outcomes in patients with type 2 diabetes mellitus (dm), chronic heart failure with reduced and preserved ejection fraction, and chronic kidney disease. recent evidence suggested that the use of sglt2 inhibitors resulted in a significant reduction in atrial fibrillation (af) over a mean follow-up duration of 2.6 years. given the possible af protective benefit with sglt2 inhibitors use.

we aim to conduct a retrospective cohort study to evaluate the impact of sglt2 inhibitors use on post-operative af (poaf) among patients undergoing cardiothoracic surgery, including coronary artery bypass grafting (cabg), valve replacement, and valve repair over a 6-year period (from 1/06/2017 to 1/07/2023). the follow-up period will be the post-operative hospital stay or 30-days, whichever is shorter, and the data will be obtained from the electronic medical records. the study outcomes will include effectiveness outcomes of incidence of poaf regardless of frequency, duration, or intervention used for termination, incidence of paroxysmal poaf, incidence of paroxysmal poaf requiring pharmacological cardioversion, incidence of hemodynamically unstable poaf requiring electrical cardioversion, incidence of persistent poaf (sustained beyond 7 days), incidence of poaf requiring anticoagulation, ischemic stroke, and safety outcomes of euglycemic diabetic ketoacidosis and urinary tract infections (uti).

Eligibility criteria:
inclusion criteria: * adults \> 18 years undergoing cardiothoracic surgery, including cabg, mechanical valve replacement, bioprosthetic valve replacement, or valve repair. * use of sglt2 inhibitors for a minimum of 1 week prior to surgery regardless of dm status. * resumption of sglt2 inhibitor after stepping down from the intensive care unit. exclusion criteria: * known af on anticoagulation. * chronic kidney disease with crcl \< 25 ml/min.
bilateral bronchoalveolar lavage in ventilator-associated pneumonia

Conditions: Pneumonia, Ventilator-Associated

Summary: the purpose of this study is to assess microbiologic concordance rates between right- and left-lung bronchoalveolar lavage cultures from patients with suspected ventilator-associated pneumonia, identify predictors of concordance, and evaluate the impact of discordant microbiology on clinicians' ability to prescribe appropriate antibiotic treatments, the investigators conducted a prospective observational study in the general intensive care unit of a large university hospital.

bronchoscopic sampling of lower respiratory tract secretions is widely used in intensive care units (icus) for the microbiological diagnosis of ventilator-associated pneumonia (vap). however, the importance of selecting a specific lung segment for sampling is still a matter of debate. non-bronchoscopic blind mini-bronchoalveolar lavage (bal) is currently used for the diagnosis of vap with satisfactory sensitivity and specificity. in the presence of pneumonia, microbiologic concordance between the left and right lungs becomes crucial. if concordance is low, the reliability of blind sampling becomes questionable. when the bacterial distribution in the right and left lungs of vap patients has been investigated using bronchoscopic sampling techniques, rates of microbiological concordance between the two specimens have varied widely (from 53% to 92%). the factors potentially associated with concordant culture yields have never been explored, and it is unclear whether the use of guided, bilateral lung sampling would actually improve the appropriateness of the antibiotic regimens prescribed for patients with suspected vap. the primary objective of this study is to assess the frequency of microbiologic concordance between the right- and left-lung samples in icu patients undergoing bronchoscopic bal performed with two different fiberoptic bronchoscopes for the suspicion of vap. secondary objectives are to identify factors associated with such concordance and to evaluate the suitability of treatments prescribed based on unilateral vs. bilateral bal cultures.

Eligibility criteria:
inclusion criteria: * invasive mechanical ventilation of ≥ 48 hours * clinically suspected pneumonia (simplified clinical pulmonary infectious score exceeded 6 or chest radiographs with a new or progressive pulmonary infiltrate in a patient with at least two of the following: purulent respiratory secretions, temperature \>38°c or \ 12,000/mm3 or \<4,000/mm3) exclusion criteria: * age \<18 years * pregnancy * absence of informed consent * an arterial oxygen partial pressure to inspired oxygen fraction ratio (pao2:fio2) of ≤150 * use of positive end-expiratory pressure (peep) \>10 cmh2o * active uncontrolled bronchospasm * unstable angina or recent (\<6 weeks) myocardial infarction * unstable arrhythmia * intracranial hypertension * platelet count ≤20,000/mm3 * international normalized ratio (inr) or activated partial thromboplastin time (aptt) ratio \>1.5 * documented treatment-limitation orders in the patient's chart